Related Experiment Video
Updated: Oct 15, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells
1Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Abstract:
Bcl-2 and related proteins are key regulators of apoptosis or programmed cell death implicated in human disease including cancer. We recently showed that cell-permeable Bcl-2 binding peptides could induce apoptosis of human myeloid leukemia in vitro and suppress its growth in severe combined immunodeficient mice. Here we report the discovery of HA14-1, a small molecule (molecular weight = 409) and nonpeptidic ligand of a Bcl-2 surface pocket, by using a computer screening strategy based on the predicted structure of Bcl-2 protein. In vitro binding studies demonstrated the interaction of HA14-1 with this Bcl-2 surface pocket that is essential for Bcl-2 biological function. HA14-1 effectively induced apoptosis of human acute myeloid leukemia (HL-60) cells overexpressing Bcl-2 protein that was associated with the decrease in mitochondrial membrane potential and activation of caspase-9 followed by caspase-3. Cytokine response modifier A, a potent inhibitor of Fas-mediated apoptosis, did not block apoptosis induced by HA14-1. Whereas HA14-1 strongly induced the death of NIH 3T3 (Apaf-1(+/+)) cells, it had little apoptotic effect on Apaf-1-deficient (Apaf-1(-/-)) mouse embryonic fibroblast cells. These data are consistent with a mechanism by which HA14-1 induces the activation of Apaf-1 and caspases, possibly by binding to Bcl-2 protein and inhibiting its function. The discovery of this cell-permeable molecule provides a chemical probe to study Bcl-2-regulated apoptotic pathways in vivo and could lead to the development of new therapeutic agents.
Insights
A novel small molecule, HA14-1, targets the Bcl-2 protein to induce apoptosis in cancer cells. This discovery offers a new chemical probe for studying programmed cell death and developing cancer therapeutics.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Bcl-2 proteins regulate apoptosis, a process crucial in diseases like cancer.
- Previous research demonstrated that Bcl-2 binding peptides could induce apoptosis in leukemia cells.
Purpose of the Study:
- To discover a small molecule inhibitor of Bcl-2.
- To investigate the mechanism of action of the novel compound HA14-1.
- To evaluate HA14-1 as a potential therapeutic agent for cancer.
Main Methods:
- Structure-based computer screening to identify Bcl-2 ligands.
- In vitro binding assays to confirm interaction with Bcl-2.
- Apoptosis induction studies in human acute myeloid leukemia cells (HL-60) and mouse embryonic fibroblast cells (Apaf-1(+/+) and Apaf-1(-/-)).
- Assessment of mitochondrial membrane potential and caspase activation (caspase-9 and caspase-3).
Main Results:
- HA14-1, a nonpeptidic small molecule, was identified as a Bcl-2 ligand.
- HA14-1 induced apoptosis in Bcl-2-overexpressing leukemia cells, involving mitochondrial pathway activation.
- Apoptosis induction by HA14-1 was dependent on Apaf-1.
- HA14-1 did not inhibit Fas-mediated apoptosis.
Conclusions:
- HA14-1 functions as a Bcl-2 inhibitor, triggering apoptosis through Apaf-1 and caspase activation.
- This small molecule serves as a valuable chemical probe for in vivo studies of Bcl-2-regulated apoptosis.
- HA14-1 holds potential for the development of novel anti-cancer therapeutics.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Cellular Injury V: Apoptosis and Autophagy
